PTGES2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1122377	0.70	17/20
SCHEMBL1122426	0.47	17/20
SCHEMBL1122657	0.69	13/20
SCHEMBL742940	0.64	11/20
SCHEMBL827377	0.60	11/20
SCHEMBL827378	0.60	11/20
SCHEMBL1122567	0.60	11/20
SCHEMBL828005	0.51	11/20
SCHEMBL828006	0.51	11/20
SCHEMBL677588	0.47	11/20
SCHEMBL503001	1.00	10/20
SCHEMBL1127421	0.54	10/20
Artemisin (SCHEMBL60303)	1.00	9/20
Artemisinin (SCHEMBL60304)	1.00	9/20
Artenimol (SCHEMBL60968)	1.00	9/20
Artemisin (SCHEMBL66817)	1.00	9/20
Artemotil (SCHEMBL60335)	0.76	9/20
Artemotil (SCHEMBL60336)	0.76	9/20
Artemotil (SCHEMBL341227)	0.76	9/20
SCHEMBL67483	0.76	9/20

Clinical trials — most relevant to PTGES2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Clinical Trial to Study the Effects of Two Drugs, Lycopene and Prednisolone in Patients With Oral Lichen Planus	PHASE4	COMPLETED
European Celecoxib Trial in Primary Breast Cancer	PHASE3	COMPLETED
Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis and Inadequate Response to ≥2 NSAIDs	PHASE3	COMPLETED
Addition of Aspirin to Standard of Care in Oral Cancer	PHASE2/PHASE3	COMPLETED
Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPA	PHASE2/PHASE3	COMPLETED
Aspirin and Renal Disease Progression in Patients With Type 2 Diabetes	PHASE3	UNKNOWN
Ramatroban/Montelukast Versus Montelukast/Placebo on the Early Allergic Reaction in Asthma Sensitive to House Dust Mite	PHASE2/PHASE3	WITHDRAWN
Desloratadine,Phenylephrine Hcl,Ibuprofen Compared to Placebo in Treatment of Symptoms Associated With Common Cold/Flu	PHASE3	SUSPENDED
Selective COX-II Inhibitor as an Adjuvant Therapy in Patients With Resectable Advanced Stomach Cancer ( Histological Staging ≥ T2N1) - A Multi-Centre Prospective Randomised Controlled Trial	PHASE3	UNKNOWN
Efficacy of Ibuprofen Chronotherapy in Healing After Surgical Extraction of the Mandibular Third Molar	PHASE2/PHASE3	UNKNOWN
Irinotecan, Cisplatin, and Radiation Therapy With or Without Celecoxib in Treating Patients With Stage II, Stage III, or Stage IV Esophageal Cancer	PHASE2	COMPLETED
Fish Oil Supplementation, Nutrigenomics and Colorectal Cancer Prevention	PHASE2	COMPLETED
Celebrex for Pain Relief After Oral Surgery	PHASE2	COMPLETED
Changes in Breast Cancer Biomarkers Using Synergistic Prostaglandin Inhibitors	PHASE1/PHASE2	COMPLETED
Ibuprofen Versus Acetaminophen for Treatment of Mild Traumatic Brain Injury	PHASE2	WITHDRAWN
Adjunctive Celecoxib in Childhood-onset OCD Study	PHASE2	UNKNOWN
Phase II A Trial of Curcumin Among Patients With Prevalent Subclinical Neoplastic Lesions (Aberrant Crypt Foci)	PHASE2	COMPLETED
Comparision Between Paracetamol and Ibuprofen in Closure of Patent Ductus Arteriosus	PHASE2	UNKNOWN
Vitamin E Supplements in Preventing Cancer in Patients at Risk of Prostate Cancer or Who Have Prostate Cancer	PHASE1	COMPLETED
Clinical Research of the Prognostic Influence of NSAIDS's Anti-inflammatory Effect on Senior Patients With Hip Fracture	nan	UNKNOWN
Lipidomics Screening of Celecoxib in ex Vivo Human Whole Blood Assay - Part B	nan	COMPLETED
Lipidomics Screening of Anti-inflammatory Drugs and Drug Candidates in Vitro - Part A	nan	ACTIVE_NOT_RECRUITING
Association and Mechanism Between Cyclooxygenase-2 and Interleukin-6 in Gastric Cancer	nan	UNKNOWN
Urinary PGE-MUM (PROSTAGLANDIN E-MAJOR URINARY METABOLITE) as Inflammatory Marker in Chronic Inflammatory Bowel Disease	nan	COMPLETED
PGE2/IL-22 Pathway in Various Forms of Eczema	nan	COMPLETED
The Role of Lymphangiogenesis in Head and Neck Cancer Metastasis	nan	UNKNOWN
Evaluation of a Novel PET Radioligand to Image Cyclooxygenase-1 (COX-1)	nan	COMPLETED
Effect of Perioperative IV Ibuprofen on Cerebral Oxygenation and Postoperative Cognition During One-Lung Ventilation	nan	NOT_YET_RECRUITING
Palmitoylethanolamide in Ulcerative Colitis	nan	NOT_YET_RECRUITING
EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish)	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a PTGES2 binder may also engage these)

Protein	Name	Similarity
Q9N0A4	—	1.000	Q9N0A4 →
Q66LN0	—	1.000	Q66LN0 →
Q8BWM0	—	1.000	Q8BWM0 →
Q7ZUC7	—	0.987	Q7ZUC7 →
Q8VDP3	—	0.978	Q8VDP3 →
Q3B8B2	—	0.976	Q3B8B2 →
Q91W34	—	0.976	Q91W34 →
Q8TDZ2	—	0.976	Q8TDZ2 →
Q8JGM4	—	0.976	Q8JGM4 →
Q99MQ3	—	0.975	Q99MQ3 →
Q1JQC5	—	0.974	Q1JQC5 →
A0PJW6	—	0.974	A0PJW6 →
D3ZBP4	—	0.974	D3ZBP4 →
Q9Y613	—	0.974	Q9Y613 →
Q9JJG9	—	0.974	Q9JJG9 →
Q4R5Q4	—	0.974	Q4R5Q4 →
Q9BQ95	—	0.974	Q9BQ95 →
B5DFG1	—	0.973	B5DFG1 →
Q91W40	—	0.973	Q91W40 →
Q8NC60	—	0.973	Q8NC60 →
Q13724	—	0.973	Q13724 →
FLAD1	FAD synthase	0.973	landscape →
Q32KL4	—	0.973	Q32KL4 →
Q68G30	—	0.973	Q68G30 →
TK2	Thymidine kinase 2, mitochondrial	0.973	landscape →
Q5RJV0	—	0.973	Q5RJV0 →
F1MH07	—	0.973	F1MH07 →
Q8VCZ9	—	0.973	Q8VCZ9 →
Q91ZJ0	—	0.973	Q91ZJ0 →
Q5R8F6	—	0.973	Q5R8F6 →